Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

ClinicalTrials.gov ID: NCT00489970

Public ClinicalTrials.gov record NCT00489970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Study identification

NCT ID
NCT00489970
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,954 participants

Conditions and interventions

Interventions

  • Taking of blood samples Procedure
  • Boostrix Biological
  • Adacel Biological

Procedure · Biological

Eligibility (public fields only)

Age range
28 Years to 73 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2007
Primary completion
Aug 31, 2011
Completion
Feb 29, 2016
Last update posted
Apr 30, 2020

2007 – 2016

United States locations

U.S. sites
37
U.S. states
22
U.S. cities
34
Facility City State ZIP Site status
GSK Investigational Site Huntsville Alabama 35802
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Mesa Arizona 85203
GSK Investigational Site Mesa Arizona 85213
GSK Investigational Site Phoenix Arizona 85014
GSK Investigational Site Tempe Arizona 85283
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site San Diego California 92103-6204
GSK Investigational Site San Diego California 92108
GSK Investigational Site Colorado Springs Colorado 80909
GSK Investigational Site Pueblo Colorado 81001
GSK Investigational Site Washington D.C. District of Columbia 20006
GSK Investigational Site Melbourne Florida 32935
GSK Investigational Site Miami Florida 33143
GSK Investigational Site Pembroke Pines Florida 33024
GSK Investigational Site Boise Idaho 83704
GSK Investigational Site Peoria Illinois 61602
GSK Investigational Site South Bend Indiana 46601
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Richland Michigan 49083
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site North Platte Nebraska 69101
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Tabor City North Carolina 28463
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Erie Pennsylvania 16505
GSK Investigational Site Grove City Pennsylvania 16127
GSK Investigational Site Johnstown Pennsylvania 15904
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Charleston South Carolina 29412
GSK Investigational Site Bristol Tennessee 37620
GSK Investigational Site Houston Texas 77024
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site West Jordan Utah 84088
GSK Investigational Site Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00489970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00489970 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →